All In Biotech

Drug Trial Radar · NCT05049902

Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication

Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Multicenter Randomized Clinical Trial of 10 and 14 Days

Last checked: Nov 19, 2026Latest source record: Jul 19, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 1,300 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,300

Actual

Start

Sep 21, 2021

Primary completion

May 30, 2023

Study completion Jun 30, 2023

Sponsor

Lead sponsor
Shandong UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Maternity and Child Care Health Center of Dezhou; Heze Municipal 3rd people's hospital; Peking University Care Luzhong Hospital; The People's Hospital of Jimo.Qingdao
First posted
Sep 20, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The researchers collect treatment-naive H.pylori-positive patients from the outpatient clinic. The subjects were randomized to receive a 10-day or 14-day course of quadruple eradication therapy. 6-8 weeks after treatment, the subjects will re-take the 13C-urea breath test. Calculate the eradication rates, adverse reaction rates, patient compliance and cost-effectiveness index of each group.

Conditions

  • Helicobacter Pylori Infection

Interventions

  • AmoxicillinDrug

    Use according to the drug combination options selected by each center.

  • ClarithromycinDrug

    Use according to the drug combination options selected by each center.

  • TetracyclineDrug

    Use according to the drug combination options selected by each center.

  • MetronidazoleDrug

    Use according to the drug combination options selected by each center.

  • Bismuth Potassium CitrateDrug

    Use according to the drug combination options selected by each center.

  • Colloidal Bismuth PectinDrug

    Use according to the drug combination options selected by each center.

  • Vonoprazan fumarateDrug

    Use according to the drug combination options selected by each center.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Eradication rateTime frame: Immediately after follow-up check.

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • The People's Hospital of Jimo.Qingdao

    Qingdao, China

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China

  • Maternity and Child Care Health Center of Dezhou

    Dezhou, Shandong, China

  • Heze Municipal 3rd people's hospital

    Heze, Shandong, China

  • Qilu hosipital

    Jinan, Shandong, China

  • PKUCare Luzhong Hospital

    Zibo, Shandong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.